Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections

American Journal of Infection Control

Volumn 38, Issue 1, 2010, Pages 78-80

  Moran, Cassandra ^a   Grussemeyer, Chelsea A ^b   Spalding, James R ^c   Benjamin Jr , Daniel K ^a,b   Reed, Shelby D ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Candida albicans; Candida glabrata; cross infection; health care costs; length of stay; mortality

Indexed keywords

ADULT; ARTICLE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA GLABRATA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FUNGUS CULTURE; HOSPITAL ADMISSION; HOSPITAL COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; CROSS INFECTION; FEMALE; FUNGEMIA; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 74449092600     PISSN: 01966553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajic.2009.06.014     Document Type: Article

References (10)

1. Falagas M.E., Apostolou K.E., and Pappas V.D. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 25 (2006) 419-425
2. Zaoutis T.E., Argon J., Chu J., et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41 (2005) 1232-1239
3. Nolla-Salas J., Sitges-Serra A., León-Gil C., et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 23 (1997) 23-30
4. Krcmery V., and Barnes A.J. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect 50 (2002) 243-260
5. Wisplinghoff H., Bischoff T., Tallent S.M., et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39 (2004) 309-317
6. Davis S.L., Vazquez J.A., and McKinnon P.S. Epidemiology, risk factors, and outcomes of Candida albicans versus non- albicans candidemia in nonneutropenic patients. Ann Pharmacother 41 (2007) 568-573
7. Moran C., Grussemeyer C.A., Spalding J.R., Benjamin Jr. D.K., and Reed S.D. Candida albicans and non- albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs. Pediatr Infect Dis J 28 (2009) 433-435
8. Rentz A.M., Halpern M.T., and Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 27 (1998) 781-788
9. Klevay M.J., Ernst E.J., Hollanbaugh J.L., et al. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 60 (2008) 273-277
10. Ben-Ami R., Weinberger M., Orni-Wasserlauff R., et al. Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol 46 (2008) 2222-2226